Curis, Inc. - Common Stock (CRIS)
1.1600
-0.0700 (-5.69%)
NASDAQ · Last Trade: Apr 8th, 1:42 AM EDT
Via Benzinga · April 2, 2025

Companies Reporting Before The Bell • Ares Management (NYSE:ARES) is expected to report quarterly earnings at $1.09 per share on revenue of $864.54 million.
Via Benzinga · February 8, 2024

Via Benzinga · January 2, 2025

CRIS stock results show that Curis beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via InvestorPlace · May 7, 2024

As of April 12, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Via Benzinga · April 12, 2024

Via Benzinga · April 4, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via Benzinga · February 9, 2024

Shares of BlackBerry Limited (NYSE: BB) fell sharply during Wednesday’s session after the company announced a proposed private offering of $160 million of convertible senior notes. BlackBerry shares tumbled 17.2% to $2.9387 on Wednesday.
Via Benzinga · January 24, 2024

Via Benzinga · January 24, 2024

Gainers Harbor Custom Development, Inc. (NASDAQ: HCDI) rose 74.2% to $1.50 after surging 24% on Thursday.
Via Benzinga · December 1, 2023

Via Benzinga · November 29, 2023

Via Benzinga · November 22, 2023

Shares of Dolby Laboratories, Inc. (NYSE: DLB) fell during Friday’s session following weak guidance.
Via Benzinga · November 17, 2023

U.S. stocks traded higher, with the Nasdaq Composite gaining around 1% on Friday. Here are some big stocks recording losses in today’s session. Corcept Therapeutics Incorporated (NASDAQ: CORT) shares fell 21% to $26.07.
Via Benzinga · September 29, 2023

Gainers Vistagen Therapeutics, Inc. (NASDAQ: VTGN) shares jumped 747.6% to $14.24 after the company announced its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of fasedienol met the primary and secondary endpoints.
Via Benzinga · August 7, 2023

Thursday, the FDA removed the partial clinical hold on Curis Inc's (NASDAQ: CRIS) TakeAim Leukemia Phase 1/2 study of emavusertib
Via Benzinga · July 7, 2023

Needham raised the price target for Applied Digital Corporation (NASDAQ: APLD) from $8.5 to $16. Needham analyst John Todaro maintained a Buy rating. Applied Digital shares fell 14.2% to close at $7.70 on Thursday.
Via Benzinga · July 7, 2023